Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Condition: Pulmonary Disease, Chronic Obstructive Intervention: Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID Sponsor: AstraZeneca Not yet recruiting - verified August 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials